ProPhase Labs, Inc. (PRPH) is a publicly traded company in the Healthcare — Medical - Pharmaceuticals industry listed on OTC. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services.
Analysis Summary
ProPhase Labs, Inc. reported revenue of $4.3M in the most recent fiscal year, growing at a 5-year CAGR of -21.4%.
Trailing-twelve-month margins: gross margin 16.4%, operating margin -498.7%, net margin -7.2%.
At the current price of $0.01, PRPH has negative trailing earnings (P/E not meaningful) and an ROE of -13.59%. Market capitalisation stands at $0M.
Balance sheet quality for PRPH: current ratio of 0.1, net debt of $8.5M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.01 |
| Market Cap | $0M |
| Exchange | OTC |
| Country | US |
Valuation Ratios
| Price / Book | -0.06 |
| EV / EBITDA | -1.31 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -1358.66% |
| Return on Invested Capital | -188.35% |
| Return on Assets | -39.44% |
| Gross Margin | 16.38% |
| Operating Margin | -498.73% |
| Net Margin | -717.43% |
Financial Health
| Debt / Equity | -2.93 |
| Current Ratio | 0.05 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PRPH | ProPhase Labs, Inc. | -13.6% | |||
| RPRX | Royalty Pharma plc | $25.9B | 24.26 | 3.81 | 12.3% |
| CORT | Corcept Therapeutics Incorporated | $12.1B | 207.35 | 16.10 | 8.4% |
| 0I3Q.L | Corcept Therapeutics Incorporated | $11.7B | 217.89 | 16.92 | 8.4% |
| LQDA | Liquidia Corporation | $6.1B | 42.09 | 30.09 | |
| KNSA | Kiniksa Pharmaceuticals International, plc | $5.9B | 72.84 | 9.24 | 13.7% |
| 0HF9.L | Amicus Therapeutics, Inc. | $5.3B | 19.37 | -12.0% | |
| PBH | Prestige Consumer Healthcare Inc. | $2.2B | 13.34 | 1.19 | 9.2% |
Price Performance
| 1 month | -54.58% |
| 3 months | -81.23% |
| Year-to-date | -96.87% |
| 1 year | -99.67% |
| 3 years | -99.94% |
| 5 years | -99.94% |
52-Week Range
| 52-week High | $6.66 |
| 52-week Low | $0.01 |
| Avg Volume (90d) | 129K |
Dividend History
| Date | Amount | Yield |
|---|---|---|
| 2022-05-24 | $3.0000 | 85227.27% |
| 2022-02-28 | $3.0000 | 85227.27% |
| 2021-05-24 | $3.0000 | 85227.27% |
| 2019-12-02 | $2.5000 | 71022.73% |
| 2019-01-09 | $2.5000 | 71022.73% |
| 2018-06-06 | $1.0000 | 28409.09% |
| 2018-05-18 | $10.0000 | 284090.91% |
Related companies: ADAP · AEMD · ALUR · AYTU · BFRI · CODX · ERNA
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of PRPH: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks